---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-026103"
form_type: "8-K"
ticker: "COGT"
cik: "0001622229"
company_name: "Cogent Biosciences, Inc."
filed_at: "2025-02-25T23:59:59+00:00"
generated_at: "2026-05-26T04:46:44.932184+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cogent Biosciences Q4/FY2024 net loss $67.9M/$255.9M; SUMMIT results due July 2025

## Summary
- Net loss Q4 $67.9M, FY $255.9M (vs $54.4M and $192.4M); R&D spend $62M/$232.7M.
- Cash, equivalents and marketable securities $287.1M at 12/31/24 plus $25M from ATM; runway into late 2026.
- Top-line SUMMIT (NonAdvSM) results expected July 2025; APEX (AdvSM) enrollment complete, data 2H 2025.
- NDA submission for bezuclastinib planned by end-2025; PEAK (GIST) top-line by end-2025.
- Preclinical IND for ErbB2 inhibitor CGT4255 and PI3Kα inhibitor CGT6297 planned in 2025.

## SEC filing metadata
- accession: 0000950170-25-026103
- form_type: 8-K
- ticker: COGT
- cik: 0001622229
- company_name: Cogent Biosciences, Inc.
- filed_at: 2025-02-25T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1622229/000095017025026103/0000950170-25-026103-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1622229/000095017025026103/cogt-20250225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-026103
- JSON: https://secwatch.observer/filing/0000950170-25-026103.json
- Plain text: https://secwatch.observer/filing/0000950170-25-026103.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.